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See Article, pages 313–318In November 2007 sorafenib became the ﬁrst systemic agent
approved for the treatment of advanced hepatocellular carcinoma
(HCC) [1]. Now, 6 years later we are still struggling to answer the
question: ‘‘What is the natural history of patients after progres-
sion on sorafenib?’’ The question is not trivial, and as recent stud-
ies have shown, it is critical for us to understand how long
patients live after they progress on sorafenib and what are the
relevant prognosticators for outcome after sorafenib. While this
information is relevant for the practicing clinician managing
patients from day to day, it is especially important to have some
benchmark for these data as we consider and design clinical stud-
ies for this population. In the past year we have seen the failure of
2 large randomized Phase III studies with promising new molec-
ular agents in patients that have progressed on sorafenib [2,3].
Both brivanib and everolimus were moved into Phase III develop-
ment based on uncontrolled Phase II data, which suggested activ-
ity based on our perceived understanding of how this population
behaves after sorafenib failure [4–6]. Until recently, we have had
to rely on assumptions from the Phase III sorafenib studies. In the
SHARP study [1], time to progression (TTP) was 5.5 months in the
treatment arm and median overall survival (OS) was 10.7 months
suggesting that patients live about another 5 months after stop-
ping sorafenib. Similarly, in the Asia-Paciﬁc sorafenib Phase III
study [7], TTP was 2.8 months and median OS was 6.5 months
in the sorafenib arm accounting for about a median 3 months
survival after stopping sorafenib. It is important to remember
that in these studies the co-primary endpoints of overall survival
and time-to symptomatic progression allowed patients to stay on
sorafenib, even after they had RECIST deﬁned radiologic progres-
sion as long as they were not symptomatic. In practice, given the
opportunity to participate in clinical trials of new second-line
agents, many clinicians will stop sorafenib when radiologic pro-
gression is documented, which may occur before the develop-
ment of symptoms. This potentially is a source of lead time
bias introduced into second line studies.
The current study by Shao and colleagues analyzed data from
a single center in Taiwan on prognostic factors for survival in
patients that progressed on ﬁrst-line therapy [8]. The studyJournal of Hepatology 20
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Open access under CC BY-NC-ND license.included 192 patients treated on 6 different front-line protocols
of systemic agents for advanced HCC. Of note, only a subset
received sorafenib in the front-line setting either as a single agent
(19%) or in combination with tegafur/uracil (28%). In addition, as
this study was from centers in Taiwan, 83% of patients had HBV
related liver disease. In this population, median OS following
ﬁrst-line therapy was only 4.0 months. The authors identiﬁed
several factors associated with a better OS in their population,
including Child-Pugh A, low CLIP score, and low ECOG perfor-
mance status (PS). In addition, a-fetoprotein >400 ng/ml upon
tumor progression and shorter TTP on front-line therapy were
associated with a worse OS and having macrovascular invasion
(MVI) upon progression had worse OS than having EHS alone.
While many of these seem intuitive, and supported by observa-
tions made in cohorts of advanced HCC [9], they raise the possi-
bility of including AFP, time on prior therapy, and separating MVI
and EHS in stratiﬁcation schemes. While having either MVI or
EHS classify patients as BCLC stage C [9], in the sorafenib Phase
III studies they were combined into one strata (i.e., the presence
or absence of MVI/EHS). The recently completed BRISK-PS study
evaluating brivanib in the second line setting suggests that these
observations regarding AFP and MVI may be relevant in study
design moving forward [2]. That is to say, perhaps they should
be included as independent stratiﬁcation factors as they seem
to be prognostic. Ongoing data analysis of the control groups
from the BRISK-PS study, as well as the everolimus study
(EVOLVE-1) should be informative.
The authors also analyzed the subset of patients that would
have qualiﬁed for one of 3 second-line clinical studies. These
studies have focused on enrolling Child Pugh A patients with good
PS, and adequate organ function. Of the 192 patients, about half,
94, would have qualiﬁed for one of the second line studies. Impor-
tantly, this subset had a different natural history than those that
did not qualify. The median survival for those patients that
qualiﬁed for the studies had a signiﬁcantly longer OS than those
that did not (Table 1). Again, while somewhat intuitive, these data
start to inform us of the impact of patient selection ‘‘bias’’ in
second-line clinical studies. Clearly, there is a subset of patients
that do better after ﬁrst-line progression than others. By enrich-
ing for these patients in Phase II uncontrolled signal ﬁnding
studies, we may be over-interpreting signiﬁcant activity from a
new agent, when it is really the expected outcome for this group.
Another recent study evaluated post-progression survival in
patients treated with sorafenib [10]. Unlike the current study,14 vol. 60 j 243–244
Table 1. Median overall survival for second-line patients depending on
whether or not they met eligibility criteria for one of the studies listed above
at progression on ﬁrst-line therapy.
Study OS eligible (mo) OS ineligible (mo)
Brivanib phase II [4] 8.3 1.7
Brivanib phase III [2] 7.8 1.7
Tivantinib phase II 8.6 2.1
OS, median overall survival; mos, months.
Adapted from Shao et al [8].
Editorialthis study was a prospective study following a cohort of 147
patients from the time they began sorafenib and evaluated TTP
with pre-speciﬁed imaging assessments. In addition, this study
was a single-center experience with a majority (57%) of patients
with HCV related HCC. Median OS was 12.7 months from the
start of the study. Several independent prognostic factors were
identiﬁed in a multi-variate Cox analysis including baseline BCLC
stage, PS, worsening liver function from CP A to CP B or C during
treatment, and radiologic tumor progression. The authors also
analyzed the pattern of progression and how that impacted over-
all survival and post-progression survival (PPS) and determined
that survival was impacted in descending order from most to
least favorable by intra-hepatic growth, extra-hepatic growth,
new intra-hepatic lesion, new extra-hepatic lesion with OS of
16.8, 10.7, 15.6, and 12.2 months, respectively. Similar to the
study by Shao et al. this study also identiﬁed BCLC stage, PS,
and CP status at the time of progression as predictors of post-pro-
gression survival (PPS) in addition to progression deﬁned by a
new extra-hepatic lesion. For patients that would qualify for a
second line study, the PPS was signiﬁcantly longer than the gen-
eral population with median OS of 13.6 months and this is
effected by the pattern of progression observed in ﬁrst-line; a
potential important new prognostic factor to include in new
studies of this population. Like the current study in this month’s
Journal, it is clear that the population of patients that are meeting
the common inclusion criteria for second-line studies have a
more favorable natural history than the general HCC population.
Since sorafenib’s approval there have been at least 5 Phase III
failures in front- and second-line HCC. To avoid this in the future,
it is critical that we change our approach to the development of
systemic therapies. For one, randomized Phase II studies must
be done to establish efﬁcacy. The lack of reliable surrogate end-
points for survival such as response, TTP, or PFS to correlate with
OS in this disease and, as highlighted in this manuscript, the clin-
ical heterogeneity of the disease make it impossible to know if a
new agent is really active unless it is compared to a control
group. In front-line this would be sorafenib and in second-line
this would be placebo. In addition, spending more time on the
development of predictive markers of response both pre-clini-
cally and in early clinical development would help enrich for
patients most likely to beneﬁt. It is quite likely that active drugs
have failed, or been interpreted as inactive because the244 Journal of Hepatology 201responding population was not well-represented in the study.
The development of tivantinib, a small molecule inhibitor of the
MET receptor can serve as a paradigm. A randomized phase II
study was performed with correlative biomarker work showing
that high Met-expression may identify a group of patients that
beneﬁt most from the drug [11]. While this is hypothesis gener-
ating, it is now a strategy for patient selection being employed in
a prospective Phase III study.
In summary, the development of systemic therapy in HCC is
still evolving. We are learning that our current expectations of
the natural history are not as we expected. In order to move
the ﬁeld forward, it is critical that we learn from negative studies,
and integrate the lessons learned into future studies; otherwise
we are likely to continue to see negative trials in HCC. As Albert
Einstein once said, ‘‘Insanity is doing the same thing over and
over again and expecting different results’’.Conﬂict of interest
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